As the child of Lebanese immigrants who fled a civil war, I was born on the Caribbean Island of Antigua and Barbuda. After the war ended, I moved to Lebanon. Motivated by the communities I was raised in, observing and experiencing the lack of access to medical care, I completed my M.D. at the Lebanese American University.
After medical school, I sought more experience in translational cancer research through postdoctoral training at the Ohio State University under the mentorship of Dr. Michael A. Caligiuri, a leading physician-scientist in immunology. I continued this research under Dr. Caligiuri at City of Hope National Medical Center (COH) in Los Angeles, California. At COH, I led a team to develop novel immunotherapies against lung cancer, acute myeloid leukemia, and pancreatic cancer by genetically modifying specific immune cells, natural killer (NK) cells, to express a Chimeric Antigen Receptor (CAR) that repurposes those NK cells to recognize and kill cancer cells. In addition to immunotherapy development, I supported the process to bring this product from the bench to the clinic from basic science research, process development, manufacturing, and regulatory compliance to obtain Federal Drug Administration approval for a phase I clinical trial. After my fellowship, I worked in biotechnology as the Vice President of Preclinical Affairs at Cytoimmune Therapeutics and continued my work on CAR-NK cells.
My body of work has been presented in over 30 peer-reviewed journals, including Gastroenterology, Molecular Therapy, and The Journal of Immunology. I also contributed to the William’s Hematology textbook, 10th edition. Additionally, this work has been presented at major conferences including the American Society of Hematology and the American Association for Cancer Research. As a result of my broad work and research experience, I received a Gabrielle’s Angel Foundation award for my work on CAR-NK therapy in acute myeloid leukemia.
Outside of medicine, I am an avid tennis player and cook, and an adventurous traveler seeking to try new foods, connect with diverse people, and immerse myself in different cultures.
Education
BS, Lebanese American University, 2012
MD, LAU Gilbert, and Rose-Marie Chagoury School of Medicine, 2016
Post-doctoral Fellowship, The Ohio State University, 2017-2019
Post-doctoral Fellowship, City of Hope National Medical Center, 2019-2021
Employment
Vice President of Preclinical Affairs at Cytoimmune Therapeutics, 2021-2022.
Publications
Chen, L., Youssef, Y., Robinson, C., Ernst, G.F., Carson, M.Y., Young, K.A., Scoville, S.D., Zhang, Z., Harris, R., Sekhri, P., Mansour, A.G., Chan, W.K., Nalin, A.P., Mao, H.C., Hughes, T., Mace, E.M., Pan, Y., Rustagi, N., Chatterjee, S.S., Gunaratne, P.H., Behbehani, G.K., Mundy-Bosse, B.L., Caligiuri MA, Freud AG. (2018). CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity, 49(3), 464-476.
Xiao, R*., Mansour, A. G.*, Huang, W., Chrislip, L. A., Wilkins, R. K., Queen, N. J., Youssef, Y., Mao, H.C., Caligiuri, M.A., & Cao, L. (2019). Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy. Molecular Therapy, 27(5), 922-932.
Mansour, A. G.*, Xiao, R., Bergin*, S. M., Huang, W., Chrislip, L. A., Zhang, J., ... & Cao, L. (2020). Enriched environment enhances NK cell maturation through hypothalamic BDNF in male mice. European Journal of Immunology, 206(4), 677-685.
Ma, R., Lu, T., Li, Z., Teng, K.Y., Mansour, A.G., Yu, M., Tian, L., Xu, B., Ma, S., Zhang, J. and Barr, T., (2021). An oncolytic virus expressing IL-15/IL-15Rα combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma. Cancer Research, 81 (13) 3635-3648.
Teng, K. Y.*, Mansour, A. G.*, Zhu, Z*., Li, Z., Tian, L., Ma, S., ... & Yu, J. (2022). Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer. Gastroenterology.
Ma, S., Tang, T., Wu, X., Mansour, A. G., Lu, T., Zhang, J., ... & Yu, J. (2022). PDGF-D− PDGFRβ signaling enhances IL-15–mediated human natural killer cell survival. Proceedings of the National Academy of Sciences, 119(3).
Book Chapters
Williams Hematology 10th edition. Anthony G. Mansour and Michael A. Caligiuri. Chapter 78: Lymphocytosis and Lymphopenia.
Mansour, A.G., Teng, K.Y., Lu, T., Barr, T. and Yu, J., 2021. CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product. In Successes and Challenges of NK Immunotherapy (pp. 213-230). Academic Press.
Selected Conference Abstracts
Yu, M., Mansour, A.G., Teng, K.Y., Sun, G., Shi, Y., & Caligiuri, M.A. "iPSC-derived natural killer cells expressing EGFR-CAR against glioblastoma.” Poster Presentation at the American Association for Cancer Research Annual Meeting, June 22-24, 2020.
Mansour, A.G., Clever D., Colleen, I., Boles, A.E., McConnel, K., Li, Z., Chrislip, L., Caligiuri, M.A., Mishra, A. Role of Mir-29b in T-cell Development and in Cutaneous T-Cell Lymphoma Pathogenesis. Oral Presentation at the American Society of Hematology Annual Meeting, December 5-8, 2020
Teng, K.Y., Mansour, A., Zheng, Z., Tien, L., Zheng, Y., Li, Z., Zhang, J., Priceman, S.J., Caligiuri, M.A., Yu, J. A potent human CAR NK cell therapy directed against pancreatic cancer. Poster Presentation at the American Association for Cancer Research Annual Meeting, April 9-14, 2021.
Mansour, A.G., Teng, K.Y., Li, Z., Zhu, Z., Chen, H., Ali, A., Zhang, J., Lu, T., Ma, S., Caligiuri, M.A., Yu, J. Off the shelf, Cord Blood FLT3 CAR-NK Cells for Immunotherapy of Acute Myeloid Leukemia. Poster presented at the American Association for Cancer Research Annual Meeting, April 8-13, 2022, in New Orleans, LA
Lu, T., Mansour, A.G., Ma, R., Bustillos, C., Li, Z., Chen, H., Teng, K.Y., Zhang, J., Caligiuri, M.A., Yu, J. Tumor-Reactive and Anti-PD-L1 Co-stimulated Natural Killer (TRACK-NK) Cells for Immunotherapy of Non-Small Cell Lung Cancer. Poster presented at the American Association for Cancer Research Annual Meeting, April 8-13, 2022, in New Orleans, LA
